A major global pharmaceutical event scheduled for early next year in Singapore has cancelled over what it calls “restrictive entry conditions”.
The asiaPLX 1 Singapore Pharma Partnering Event was set to run in February 2022, but has been postponed to early 2023.
Organiser RauCon said Singapore’s restrictive entry conditions for delegates from important pharmaceutical countries made hosting the event impossible.
The restrictions include complete entry bans for a number of countries, up to four pre-departure and on-arrival PCR tests depending on the country of departure, seven-days or 14-days quarantines, or a mixture of various measures.
“The reluctance of executives to travel to Singapore under these confusing circumstances has led to a globally imbalanced composition of registrants which would not have supported this event’s claim to be a highly performant platform for worldwide business development,” the organisers stated.